Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The firm currently has a $8.75 target price on the stock.

According to Zacks, “Trillium Therapeutics Inc. is an immuno-oncology company. It engages in developing therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRP?Fc and a CD200 monoclonal antibody, which target two key immunoregulatory spathway that tumor cells exploit to evade the host immune system. Trillium Therapeutics Inc. is based in Canada. “

Several other analysts have also issued reports on the company. Bloom Burton restated a “buy” rating on shares of Trillium Therapeutics in a research note on Friday, November 4th. Leerink Swann reiterated an “outperform” rating and set a $20.00 target price on shares of Trillium Therapeutics in a research note on Thursday, November 3rd. Cowen and Company reiterated a “buy” rating on shares of Trillium Therapeutics in a research note on Thursday, November 3rd. BTIG Research assumed coverage on Trillium Therapeutics in a research note on Thursday, October 6th. They set a “buy” rating and a $21.00 target price on the stock. Finally, Ladenburg Thalmann assumed coverage on Trillium Therapeutics in a research note on Wednesday, August 3rd. They set a “buy” rating and a $18.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $21.15.

Analyst Recommendations for Trillium Therapeutics (NASDAQ:TRIL)

Trillium Therapeutics (NASDAQ:TRIL) opened at 8.75 on Wednesday. The firm has a 50-day moving average price of $12.75 and a 200 day moving average price of $11.39. The company’s market cap is $68.37 million. Trillium Therapeutics has a 12 month low of $6.62 and a 12 month high of $17.70.

A number of large investors have recently modified their holdings of the company. Creative Planning increased its stake in shares of Trillium Therapeutics by 37.3% in the third quarter. Creative Planning now owns 8,100 shares of the company’s stock worth $120,000 after buying an additional 2,200 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in shares of Trillium Therapeutics during the first quarter worth about $100,000. Wells Fargo & Company MN increased its stake in shares of Trillium Therapeutics by 1,080.0% in the third quarter. Wells Fargo & Company MN now owns 11,800 shares of the company’s stock worth $175,000 after buying an additional 10,800 shares in the last quarter. K2 Principal Fund L.P. bought a new stake in shares of Trillium Therapeutics during the second quarter worth about $131,000. Finally, Susquehanna International Group LLP bought a new stake in shares of Trillium Therapeutics during the third quarter worth about $372,000. 41.39% of the stock is currently owned by institutional investors and hedge funds.

5 Day Chart for NASDAQ:TRIL

Receive News & Stock Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related stocks with our FREE daily email newsletter.